Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A
Report of the American College of Cardiology/American Heart Association Task Force on …

The recommendations listed in this guideline are, whenever possible, evidence-based. An
initial extensive evidence review, which included literature derived from research involving …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple
and in some ways conflicting. The treatment algorithm usually includes different types of …

Background—Treatment options for pulmonary arterial hypertension target the prostacyclin,
endothelin, or nitric oxide pathways. Tadalafil, a phosphodiesterase type-5 inhibitor …

Aims There is no cure for pulmonary arterial hypertension, but current approved treatment
options include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type …

Background Paediatric pulmonary hypertension, is an important cause of morbidity and
mortality, and is insufficiently characterised in children. The Tracking Outcomes and Practice …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …